Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 7711 results

  1. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460

    Awaiting development [GID-TA11534] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development [GID-TA11661] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

    Awaiting development [GID-TA11516] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Awaiting development [GID-TA11467] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

    In development [GID-TA11485] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  8. Nirogacestat for treating desmoid tumours [ID6453]

    Awaiting development [GID-TA11559] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468

    Awaiting development [GID-TA11581] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471

    Awaiting development [GID-TA11490] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    Awaiting development [GID-TA11560] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Slide sheets for repositioning or moving a person on or from a bed: Late Stage Assessment

    In development [GID-HTE10051] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  13. Bed frames for adults in acute settings

    In development [GID-HTE10050] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  14. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (DG62)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome

    Diagnostics guidance
    Published
    19 December 2024
    View recommendations

    Sections for DG62

  15. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development [GID-TA11379] Expected publication date: TBC

    Technology appraisal guidance
    In development